NICE announces more people eligible for nusinersen following review of Managed Access Agreement

More people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from the treatment, says NICE.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date
Register

Existing members Sign in